Q1 2024 Financial Results May 2, 2024 1 Agios conference call participants TOPIC PARTICIPANT Chris Taylor, VP Investor Relations and Corporate Introduction Communications Business Update Brian Goff, Chief Executive Officer Sarah Gheuens, M.D., Ph.D., ...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Divya Rao - TD Cowen Eric Schmidt - Cantor Alec Stranahan - Bank of America T ...

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $1.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.59%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.64 per share when it actually produced a loss of $1.72, delivering a surprise of -4.88%.Over the last four quarters, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-0662915 (State or Other Jurisdiction of (I ...

Exhibit 99.1 Agios Reports Business Highlights and First Quarter 2024 Financial Results – Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion- Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion- Dependent Alpha- or Beta-Thalassemia in January – – Phase 3 Readouts from Mitapivat RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T i ...

– Report Highlights Company's Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong Corporate Governance – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the Biotechnology and Pharmaceuticals Industry and the United Nations Sustainable Development Goals (UN SDGs) – CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today ...

Agios Pharmaceuticals, Inc. (AGIO) reported a loss of $1.72 per share in fourth-quarter 2023, wider than the Zacks Consensus Estimate of a loss of $1.64. In the year-ago quarter, the company posted a loss of 67 cents per share.AGIO reported revenues of $7.1 million, which also missed the Zacks Consensus Estimate of $8 million. In the year-ago quarter, the company recorded revenues of $4.3 million.Quarter in DetailIn the reported quarter, revenues were generated entirely from product revenues of Agios’ only ...

Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2023 Earnings Conference Call February 15, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Cecilia Jones - Chief Financial Officer Tsveta Milanova - Chief Commercial Officer Sarah Gheuens - Chief Medical Officer, Head of R&D Conference Call Participants Chris Raymond - Piper Sandler Danielle Brill - Raymond James Gregory Renza - RBC Capital Markets Tess Romero - JP ...

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.72 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to earnings of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.88%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.69 per share when it actually produced a loss of $1.64, delivering a surprise of 2.96%.Over the last four quarter ...

Q4 and Full Year 2022 Financial Results February 23, 2023 Agios conference call participants ...